MedPath

GILEAD SCIENCES SL

🇺🇸United States
Ownership
-
Established
1994-01-01
Employees
-
Market Cap
$95.8B
Website
http://www.gilead.com/about/worldwide-operations/europe/spain

Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies

Phase 1
Completed
Conditions
Chronic Lymphocytic Leukemia (CLL)
Lymphoma, Non-Hodgkin (NHL)
Acute Myeloid Leukemia (AML)
Multiple Myeloma (MM)
Interventions
First Posted Date
2008-07-04
Last Posted Date
2012-08-31
Lead Sponsor
Gilead Sciences
Target Recruit Count
192
Registration Number
NCT00710528
Locations
🇺🇸

Sarah Cannon Research Institute, Nashville, Tennessee, United States

🇺🇸

The Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, Maryland, United States

🇺🇸

Weill Medical College of Cornell, New York, New York, United States

and more 6 locations

Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

Phase 3
Completed
Conditions
HIV Infection
Interventions
Drug: RAL placebo
Drug: Background regimen
First Posted Date
2008-07-02
Last Posted Date
2016-05-30
Lead Sponsor
Gilead Sciences
Target Recruit Count
724
Registration Number
NCT00708162
Locations
🇺🇸

Whitman-Walker Clinic, Washington, District of Columbia, United States

🇺🇸

Orlando Immunology Center, Orlando, Florida, United States

🇺🇸

Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

and more 176 locations

CRITIC - Treatment of Candidemia and Invasive Candidiasis

Phase 4
Completed
Conditions
Candidemia
Invasive Candidiasis
Interventions
First Posted Date
2008-05-02
Last Posted Date
2009-03-27
Lead Sponsor
Gilead Sciences
Target Recruit Count
39
Registration Number
NCT00670657
Locations
🇮🇹

Gilead Sciences Srl, Milan, Italy

Efficacy Study of CYT997 in Multiple Myeloma

Phase 2
Terminated
Conditions
Relapsed and Refractory Multiple Myeloma
Interventions
First Posted Date
2008-04-22
Last Posted Date
2018-06-08
Lead Sponsor
Gilead Sciences
Target Recruit Count
5
Registration Number
NCT00664378
Locations
🇦🇺

The Alfred Hospital, Melbourne, Victoria, Australia

Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma

Phase 1
Terminated
Conditions
Glioblastoma Multiforme
Interventions
First Posted Date
2008-04-02
Last Posted Date
2013-05-03
Lead Sponsor
Gilead Sciences
Target Recruit Count
20
Registration Number
NCT00650949
Locations
🇦🇺

Royal North Shore Hospital, St-Leonards, New South Wales, Australia

🇦🇺

Flinders Medical Centre, Bedford Park, South Australia, Australia

🇦🇺

Gold Coast Hospital, Southport, Queensland, Australia

and more 1 locations

Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue

Phase 2
Completed
Conditions
Lipodystrophy
Interventions
First Posted Date
2008-04-01
Last Posted Date
2008-06-30
Lead Sponsor
Gilead Sciences
Target Recruit Count
100
Registration Number
NCT00647946
Locations
🇬🇧

Gilead Sciences, Abingdon, Cambridge, United Kingdom

Metabolic Impact Assessment of Tenofovir Disoproxil Fumarate on Non-HIV-1 Infected Healthy Adult Male Volunteers

Phase 4
Completed
Conditions
HIV Infections
Interventions
First Posted Date
2008-04-01
Last Posted Date
2008-04-01
Lead Sponsor
Gilead Sciences
Target Recruit Count
8
Registration Number
NCT00648817
Locations
🇬🇧

Chelsea and Westminster Hospital, London, United Kingdom

CHARM: Chronic Hepatitis B Antihepadnaviral Resistance Mutation Study

Completed
Conditions
Chronic Hepatitis B
Interventions
Other: No intervention
First Posted Date
2008-03-28
Last Posted Date
2011-11-22
Lead Sponsor
Gilead Sciences
Target Recruit Count
788
Registration Number
NCT00645736
Locations
🇦🇺

Gilead Sciences Pty Ltd, East Melbourne, Victoria, Australia

PK Study of Tacrolimus and Cyclosporine When Co-Administered With Adefovir Dipivoxil in Post-Liver Transplant Patients

Phase 2
Completed
Conditions
Hepatitis B
Interventions
First Posted Date
2008-03-27
Last Posted Date
2008-04-10
Lead Sponsor
Gilead Sciences
Target Recruit Count
16
Registration Number
NCT00644761
Locations
🇺🇸

University of Miami, Miami, Florida, United States

🇺🇸

University of California, San Francisco, San Francisco, California, United States

🇺🇸

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 8 locations

Open Label Study of Pharmacokinetics and Safety of Dose of Adefovir Dipivoxil in Children and Adolescents With HBV

Phase 1
Completed
Conditions
Hepatitis B
Interventions
First Posted Date
2008-03-27
Last Posted Date
2008-03-27
Lead Sponsor
Gilead Sciences
Target Recruit Count
47
Registration Number
NCT00645294
Locations
🇬🇧

King's College Hospital, London, England, United Kingdom

🇩🇪

Standort Lindwurmstrasse, Munchen, Germany

🇵🇱

Klinika Gastroenterologii, Warszawa, Poland

and more 7 locations
© Copyright 2025. All Rights Reserved by MedPath